20th week of 2009 patent applcation highlights part 48 |
Patent application number | Title | Published |
20090124535 | VISCOUS TERPOLYMERS AS DRUG DELIVERY PLATFORM - Disclosed are terpolymer compositions of lactide, glycolide, and caprolactone and methods of making such polymers with an initiator. Methods of using the terpolymers as a drug delivery platform are also disclosed. | 2009-05-14 |
20090124536 | CALCIUM PHOSPHATE/SULFATE-BASED BONE IMPLANT COMPOSITION - A bone implant composition, the composition comprising calcium sulphate and slowly soluble source of calcium, orthophosphate and hydroxyl ions. The composition may be provided in powder or granulated form. | 2009-05-14 |
20090124537 | Screening method for bone morphogenetic mimetics - Disclosed are methods for identifying agents which modulate the activity of bone morphogenetic protein-7. These methods for identifying agents utilize bone morphogenetic protein receptors, specifically the daf-4 receptor, and more specifically the extracellular domain of the daf-4 receptor. Agents identified by the methods are also described as well as compositions comprising the agents and methods of treating a subject using the agents or compositions. | 2009-05-14 |
20090124538 | Selective R-cadherin antagonists and methods - An isolated peptide useful as a selective antagonist of mammalian R-cadherin comprises 3 to 30 amino acid residues, three contiguous residues of the peptide having the amino acid sequence Ile-Xaa-Ser; wherein Xaa is an amino acid residue selected from the group consisting of Asp, Asn, Glu, and Gln. Preferably Xaa is Asp or Asn. In one preferred embodiment the peptide is a cyclic peptide having 3 to 10 amino acid residues arranged in a ring. The selective R-cadherin antagonist peptides of the invention are useful for inhibiting the targeting of stem cells, such as endothelial precursor cells, to developing vasculature, for inhibiting R-cadherin mediated cellular adhesion, and for inhibiting retinal angiogenesis. | 2009-05-14 |
20090124539 | Methods of treating infection - The present invention relates to methods of inhibiting the proliferation of bacteria for either ex vivo or in vivo use. The invention also relates to methods of treating a patient infected with an antibiotic resistant bacteria by administering a pharmaceutical composition comprising an Empedopeptin; methods of sanitizing surfaces and instruments; and methods of assaying bacteria for Empedopeptin resistance. | 2009-05-14 |
20090124540 | Anti-adhesion composites and methods of use thereof - Described herein are composites that inhibit or reduce adhesion between two or more tissues. Also described herein are methods of using the composites. | 2009-05-14 |
20090124541 | Method for the recovery and application of novel human defensins as biologically active proteins for the treatment of infections and other diseases - The invention relates to the novel peptides, derived from human blood, hBD-5 (human beta-defensin-5), hBD-6, hBD-7, hBD-8, hBD-10, hBD-11, hBD-12, hBD-13, hBD-14, hBD-15, hBD-16, hBD-17, hBD-18, hBD-19, hBD-20, hBD-22, hBD-23, hBD-24, hBD-25, hBD-26, hBD-27, hBD-28, hBD-29, hBD-30, hBD-31 and hBD-32 and their derivatives whose structure was elucidated for the purpose of therapeutic, diagnostic and commercial use as medicaments. The peptides can be prepared by biotechnological, recombinant methods, by chemical synthesis as well as by proteolysis from corresponding precursor proteins. | 2009-05-14 |
20090124542 | METHODS AND REAGENTS FOR TREATMENT AND DIAGNOSIS OF AGE-RELATED MACULAR DEGENERATION - The invention relates to Factor H gene polymorphisms and haplotypes associated with an elevated or a reduced risk of AMD. The invention provides methods and reagents for diagnosis and treatment of AMD. | 2009-05-14 |
20090124543 | ACTIVITY DEPENDENT NEUROTROPHIC FACTOR III (ADNF III) - The present invention relates generally to Activity Dependent Neurotrophic Factor III (ADNF III), also known as Activity Dependent Neuroprotective Protein (ADNP). More particularly, the present invention relates to nucleic acid sequences encoding ADNF III polypeptides; ADNF III polypeptides encoded by such nucleic acid sequences; antibodies to ADNF III polypeptides; and methods of using such ADNF III polypeptides for the treatment of neurological deficiencies and for the prevention of cell death associated with (1) gp120, the envelope protein from HIV; (2) N-methyl-D-aspartic acid (excito-toxicity); (3) tetrodotoxin (blockage of electrical activity); and (4) β-amyloid peptide, a substance related to neuronal degeneration in Alzheimer's disease. | 2009-05-14 |
20090124544 | COMPOSITIONS AND METHODS FOR THE PREPARATION OF PROTEASE RESISTANT HUMAN GROWTH HORMONE GLYCOSYLATION MUTANTS - The present invention relates to protease resistant mutants of human growth hormone, which contain newly introduced proteolysis resistant mutations and N-linked or O-linked glycosylation site(s), such that these recombinantly produced polypeptides have glycosylation patterns distinctly different from that of the naturally occurring human growth hormone. The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed. Further disclosed are pharmaceutical compositions comprising the mutants and method for using the mutants. | 2009-05-14 |
20090124545 | NOVEL NUCLEIC ACID ENCODING A NOVEL PROTEIN OF CANDIDA ALBICANS AND USES THEREOF | 2009-05-14 |
20090124546 | Antimicrobially Active Peptides - An antimicrobially active peptide comprises the DCD protein or a fragment of DCD, preferably derived from the C-terminal region. | 2009-05-14 |
20090124547 | COMPOUNDS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC MOIETIES TO NERVE CELLS - A compound for delivering a non-cytotoxic therapeutic moiety into nerve cells, the compound having the general formula: | 2009-05-14 |
20090124548 | Method of Using Fish Plasma Components to Inhibit Glial Scarring and Promote Functional Recovery in the Mammalian CNS - A method includes applying salmon fibrin at a central nervous system injury site. For example, applying salmon fibrin can include injecting salmon fibrin. The method can also include causing the suppression of astrocyte activation, whereby glial scarring is at least reduced. The functional recovery of a patient who has suffered a central nervous system injury is promoted according to this method. | 2009-05-14 |
20090124549 | METHODS FOR PRODUCING AN IMMUNE RESPONSE TO TUBERCULOSIS - Methods for producing an immune response to | 2009-05-14 |
20090124550 | Thrombin peptide derivative dimers - Disclosed are thrombin peptide derivative dimers comprising two polypeptides having the amino acid sequence Arg-Gly-Asp-Ala-Cys-Glu-Gly-Asp-Ser-Gly-Gly-Pro-Phe-Val (SEQ ID NO:2), or a C-terminal truncated fragment of the polypeptide having at least six amino acids. Zero, one, two, or three amino acids in the polypeptide or polypeptide fragment differ from the corresponding position of SEQ ID NO:2. Also disclosed are methods of treating a subject in need of treatment with a thrombin receptor agonist. The methods comprise the step of administering an effective amount of the thrombin peptide derivative described above. | 2009-05-14 |
20090124551 | METHODS OF ADMINISTERING BONE HEALTH COMPOSITIONS DERIVED FROM MILK - The invention relates to bone health compositions comprising an acidic protein fraction of milk, to a method of producing said bone health composition, to methods of treatment comprising said bone health compositions and to medicinal uses of said bone health compositions. One broad aspect of the invention provides a bone health composition comprising an acidic protein fraction derived from milk, from a component of milk, from whey, from hydrolysates thereof, or from a combination thereof wherein the composition does not comprise caseinoglycomacropeptide (CGMP). Another broad aspect provides a method of manufacturing the composition of the invention using anion exchange chromatography. | 2009-05-14 |
20090124552 | Methods and Compositions for Regenerating Connective Tissue - Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament. | 2009-05-14 |
20090124553 | Suppression of inflammation associated with transplantation using an epsilon PKC inhibitor - The described compositions and methods relate to the suppression of inflammatory responses following allograft transplantation by administering an inhibitor of epsilon protein kinases c (εPKC) following transplantation. | 2009-05-14 |
20090124554 | BUCCAL, POLAR AND NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING PAIN - Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring agent; formulation II: aqueous polar solvent, active compound, optionally flavoring agent, and propellant; formulation III: non-polar solvent, active compound, and optional flavoring agent; and formulation IV: non-polar solvent, active compound, optional flavoring agent, and propellant. | 2009-05-14 |
20090124555 | USE OF HISTOGRANIN AND HISTOGRANIN-LIKE COMPOUNDS AS INHIBITORS OF P2X7 RECEPTOR FUNCTION AND AS ANTI-ARTHRITIC AGENTS - The invention relates to the use of Histogranin-like compounds to reduce P2X | 2009-05-14 |
20090124556 | Peptides Exhibiting Efficacies of Improvement in Skin Conditions or Treatment of Periodental Diseases - The present invention relates to a composition for improving a skin condition or treating a periodontal disease, which comprises as an active ingredient a basic fibroblast growth factor-derived peptide. The peptides of this invention exhibit superior efficacies and much better stability and skin permeation than natural-occurring bFGF. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on improvement in skin conditions and treatment of periodontal diseases. In addition, the peptides of this invention can be advantageously applied to pharmaceutical compositions, cosmetics, tooth-paste and compositions for mouth cleaning and caring. | 2009-05-14 |
20090124557 | Compositions and methods for treating cancer - A composition which comprises a chimeric polypeptide is provided. The chimeric polypeptide having a flagellin amino acid sequence and a mucin 1 amino acid sequence which includes at least a 7 amino acid sequence of the mucin 1 tandem repeat which can be used to elicit an immune response against MUC1—expressing cancerous cells. Also provided is a method of treating cancer such as a cancer of a glandular epithelium in which MUC1 is overexpressed using the composition of the present invention. | 2009-05-14 |
20090124558 | COMPOSITIONS AND METHODS FOR TREATING NEURAL ANOXIA AND SPREADING DEPRESSION - Compositions and methods for protecting neural tissue (e.g., neurons) from anoxia and spreading depression (SD) involve inhibiting the cGMP-dependent protein kinase (PKG) pathway. It was discovered that the PKG pathway plays a crucial role in regulating SD and tolerance to anoxia in the central nervous system (CNS). Inhibition of the PKG pathway greatly reduces SD and increases tolerance to anoxia (i.e., hypoxia), while activation of the pathway exacerbates SD pathology. The compositions and methods can be used to treat any condition associated with SD or anoxia, including stroke, spinal cord injury, neurogenerative disease, dizziness, headaches, and migraines. | 2009-05-14 |
20090124559 | Soft Protease Inhibitors and Pro-Soft Forms Thereof - The invention provides compounds and methods for inhibiting proteases. One aspect of the invention features pro-soft inhibitors which react with an activating protease to release an active inhibitor moiety in proximity to a target protease. In certain instances, compounds inhibit proteasomes and/or post-proline cleaving enzymes (PPCE), such as dipeptidyl peptidase IV. The compounds of the invention provide a better therapeutic index, owing in part to reduced toxicity and/or improved specificity for the targeted protease. | 2009-05-14 |
20090124560 | Composition Containing Peptide as Active Ingredient - The invention provides a composition used for promoting glucose uptake, which comprises a peptide having an effect of promoting glucose uptake as the active ingredient, as well as a composition comprising a dipeptide containing leucine and/or isoleucine as the active ingredient. The composition is effective in preventing or treating diabetes mellitus or an elevation of blood glucose level, in promoting glycogen storage, or in enhancing physical strength, enhancing athletic ability, improving endurance performance or relieving fatigue. | 2009-05-14 |
20090124561 | DIHYDROXYPHENYL COMPOUNDS AND GLUCOSIDE COMPOUNDS THEREOF - A skin cosmetic composition comprising the compound represented by the following formula (1): | 2009-05-14 |
20090124562 | Versipelostatin derivative, anti-cancer agent and processes for production of the derivative and agent - Provided is a new anti-cancer agent lower in cell toxicity. | 2009-05-14 |
20090124563 | ORAL EXTENDED-RELEASE COMPOSITION - The invention is directed to controlled release formulations containing drugs which are preferably considered sparingly soluble to insoluble and which are suitable for administration to a patient in need of treatment related thereto, and methods of manufacturing the same. | 2009-05-14 |
20090124564 | Compositions and methods for regulating apoptosis - Methods and pharmaceutical compositions for regulating apoptosis and treating pathologies associated with disregulated apoptosis are provided. Specifically the present invention provides agents capable of modulating the expression of an MCD-containing protein (e.g., Mtch2) capable of tBID binding activity and/or the tBID binding activity of the MCD-containing protein. | 2009-05-14 |
20090124565 | COMPOSITION COMPRISING AT LEAST ONE NUCLEOSIDIC MOIETY AS A THERAPEUTIC AGENT, AND CKC - Composition comprising at least one nucleosidic moiety and cetalkonium chloride and pharmaceutical use thereof for prevention, treatment or relief of eye, lung, and/or respiratory tract conditions. | 2009-05-14 |
20090124566 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ERYTHROCYTE DISEASES - Methods to determine the susceptibility of a subject to erythrocyte diseases are provided. The methods comprise determining the miRNA compositions of erythrocytes from the subject. The present invention has discovered that erythrocytes comprise microRNA (miRNA) populations and the populations can be profiled or analyzed and used to determine the susceptibility for disease. The miRNA compositions can also be used to determine the severity of erythrocyte disease, and the features and clinical phenotypes of the erythrocyte disorders. Also provided are pharmaceutical compositions comprising erythrocyte miRNAs and methods for the treatment of a subject with an erythrocyte disease. In other embodiments of the invention, the miRNAs can be used to increase the life-span of erythrocytes through the introduction of an erythrocyte miRNA. | 2009-05-14 |
20090124567 | Influenza Therapeutic - The present invention provides methods and compositions for inhibiting influenza infection and/or replication based on the phenomenon of RNA interference (RNAi) well as systems for identifying effective siRNAs and shRNAs for inhibiting influenza virus and systems for studying influenza virus infective mechanisms. The invention also provides methods and compositions for inhibiting infection, pathogenicity and/or replication of other infectious agents, particularly those that infect cells that are directly accessible from outside the body, e.g., skin cells or mucosal cells. In addition, the invention provides compositions comprising an RNAi-inducing entity, e.g., an siRNA, shRNA, or RNAi-inducing vector targeted to an influenza virus transcript and any of a variety of delivery agents. The invention further includes methods of use of the compositions for treatment of influenza. | 2009-05-14 |
20090124568 | USE OF STEM CELLS TO GENERATE INNER EAR CELLS - This invention relates generally to methods and compositions for inducing stem cell or progenitor cell differentiation, and more particularly to methods and compositions for inducing differentiation of stem cells and/or progenitor cells into cells that function within the inner ear. | 2009-05-14 |
20090124569 | INHIBITION AND TREATMENT OF PROSTATE CANCER METASTASIS - The present invention provides compounds and methods of inhibiting and treating metastatic prostate cancer. The compounds include MEK4 inhibitors. In another aspect the invention provides methods of identifying inhibitors of metastatic prostate cancer by screening for inhibitors of MEK4. | 2009-05-14 |
20090124570 | Methods and Compositions for Facilitating Tissue Repair and Diagnosing, Preventing, and Treating Fibrosis - Compositions and methods for facilitating tissue repair by enhancing the actions of BIGH3 or at least one of its downstream effector molecules in injured tissue, and for the diagnosis, prophylactic and therapeutic treatment of fibrosis by inhibiting the actions of BIGH3 or at least one of its downstream effector molecules, such as PU.1 transcription factor and MMP14. Other disclosed methods include methods of screening and/or identifying compounds useful for facilitating tissue repair, treating fibrosis, or for altering the accumulation or deposition of collagen, comprising contacting BIGH3 or its downstream effector molecules, such as PU.1 or MMP14, with a substance and subsequently determining the effects of the substance on the activity of BIGH3, PU.1, or MMP14. | 2009-05-14 |
20090124571 | METHOD FOR THE SYNTHESIS OF OLIGONUCLEOTIDE DERIVATIVES - Method for the synthesis of nucleotide derivatives wherein molecules of interest are grafted on the oligonucleotide with the help of a “click chemistry” reaction between an azide function on the molecule of interest and an alkyne function on the oligonucleotide, or between an alkyne function on the molecule of interest and an azide function on the oligonucleotide. | 2009-05-14 |
20090124572 | Iron-containing nutritional supplement - The present invention relates to a nutritional supplement, and particularly, to an oral nutritional supplement which contains an iron fortificant comprising a ferric pyrophosphate chelate. The nutritional supplement can also include vitamins, non-ferrous minerals, and other ingredients. The nutritional supplement is useful for providing iron to animals, and is intended to be used, for example, to administer iron to animals and humans, including individuals afflicted with anemia of chronic disease, pregnant women, women anticipating pregnancy, and lactating women. The compositions and methods can also be used to administer iron together with one or more vitamins or non-ferrous minerals to men, women, children or infants, as well as to animals. | 2009-05-14 |
20090124573 | IMMUNOMODULATING COMPOUNDS AND RELATED COMPOSITIONS AND METHODS - Provided herein are compounds, compositions and methods for balancing a T-helper cell profile and in particular Th1, Th2, Th17 and Treg cell profiles, and related methods and compositions for treating or preventing an inflammatory condition associated with an imbalance of a T-helper cell profile. | 2009-05-14 |
20090124574 | Carotenoid analogs and derivatives for the prevention of platelet aggregation - The presently described embodiments are directed to compositions that include one or more carotenoid analogs or derivatives for use in the treatment of a disorder associated with platelet aggregation. Certain embodiments provide for the use of said carotenoid analogs or derivatives in preparing compositions suitable for use in such treatments. Further embodiments provide for pharmaceutical compositions that include one or more carotenoid analogs or derivatives in combination with one or more additional compositions or medicaments suitable for the treatment of a disorder associated with platelet aggregation. Yet farther embodiments provide for methods of treating a disorder associated with platelet aggregation that include administering to a subject who would benefit from such treatment pharmaceutical compositions suitable for inhibiting platelet aggregation in a subject undergoing said treatments, and that include carotenoid analogs or derivatives, optionally in combination with one or more additional antiplatelet agents. | 2009-05-14 |
20090124575 | Method of Inhibition the Growth of Algae - To inhibit the growth of algae, glucosamine is added into water needed to be treated. | 2009-05-14 |
20090124576 | Triazine Derivatives - Disclosed are triazine derivatives of formula | 2009-05-14 |
20090124577 | Intermediate Compounds for the Preparation of an Angiotensin II Receptor Antagonist - It comprises new substituted 4-valinylmethylphenyl boronic acids of formula (II) and their derivatives and also its preparation process. It also comprises a preparation process of Valsartan (I) from such intermediates. The process comprises the reaction of the new 4-valinylmethylphenyl boronic compounds with a (halophenyl)tetrazole compound which proceeds with high yields. The process is particularly advantageous in its practical industrial realization because it avoids the use of azide derivatives and also the use of expensive biphenyl intermediates. | 2009-05-14 |
20090124578 | SPIRO-OXAZOLIDINONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS - Compounds in accord with Formula I: | 2009-05-14 |
20090124579 | Systems and Methods For Determination of Compounds for Stimulation or Inhibition of Neocalcification - Disclosed are systems and methods as may be used for development of compounds that can be utilized for prevention of pathological calcification. Disclosed are functional models can represent in great detail the first steps in protein-membrane interaction leading to calcification. Disclosed compounds include those that interfere with pathologic calcification processes and thus may be used as part of a formulation or composition for preventing pathological calcifications. Modeling methods and systems can include in vitro and/or in silico dynamic molecular modeling of biological materials including representative mineralization models in conjunction with substances that can affect normal or pathogenic calcification processes. Disclosed models can examine interactions of biological components involved in calcification including calcium, inorganic phosphate, phosphatidylserine, and annexin-5 protein. | 2009-05-14 |
20090124580 | PRODRUGS OF 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES - The present disclosure provides prodrugs of biologically active 2,4-pyrimidinediamine compounds, compositions comprising the prodrugs, intermediates and methods for synthesizing the prodrugs and methods of using the prodrugs in a variety of applications. | 2009-05-14 |
20090124581 | Novel phosphonic acid compounds as inhibitors of serine proteases - The present invention is directed to phosphonic acid compounds useful as serine protease inhibitors, compositions thereof and methods for treating inflammatory and serine protease mediated disorders. | 2009-05-14 |
20090124582 | Acyloxyalkyl Carbamate Prodrugs, Methods of Synthesis, and Use - Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, pharmaceutical compositions comprising acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of making prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof, methods of using prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and pharmaceutical compositions thereof for treating or preventing diseases or disorders such as spasticity or gastroesophageal reflux disease are disclosed. Acyloxyalkyl carbamate prodrugs of 3-aminopropylphosphonous acid, 3-aminopropylphosphinic acid, and analogs thereof and sustained release oral dosage forms thereof, which are suitable for oral administration, are also disclosed. | 2009-05-14 |
20090124583 | 7-N-substituted phenyl tetracycline compounds - 7-substituted tetracycline compounds, methods of treating tetracycline responsive states, and pharmaceutical compositions containing the 7-substituted tetracycline compounds are described. | 2009-05-14 |
20090124584 | REGENERATION OF VAGINAL TISSUE WITH NON-SYSTEMIC VAGINAL ADMINISTRATION OF ESTROGEN - Methods and formulations for the regeneration of vaginal tissue and vaginal cell health resulting from vaginal cell hypoxia in a human female. A pharmaceutical composition for topical non-systemic administration is formulated containing a hormonal agent administered to the vagina, vulvar area of the individual undergoing treatment. | 2009-05-14 |
20090124585 | Novel Crystalline Pharmaceutical Product - There are provided crystalline particles of unsolvated Form 1 polymorph of the compound of formula (I): | 2009-05-14 |
20090124586 | Aqueous-based pharmaceutical composition - An aqueous pharmaceutical composition which is capable of being sprayed into the nasal cavity of an individual and which comprises: (A) a pharmaceutically effective amount of solid particles of medicament which is effective in treating a bodily condition by virtue of its being present on the mucosal surfaces of the nasal cavity; and (B) a suspending agent in an amount effective to maintain said particles dispersed uniformly in the composition and to impart to the composition the following thixotropic properties: (i) the viscosity of the position in unsheared form is relatively high, with the composition being in gel-like form; (ii) as the composition is subjected to shear (shaken) in preparation for spraying, the viscosity of the composition becomes relatively low and such that the composition in the form of a mist flows readily into the nasal passages for deposit on the mucosal surfaces of the nasal cavity; and (D) in deposited form on the mucosal surfaces, the viscosity of the composition is relatively high and such that it resists being cleared from the mucosal surfaces by the inherent mucocillary forces which are present in the nasal cavity, a method of use of the composition and a method for preparation of the composition, including in preferred form the use of anti-inflammatory steroid, for example, triamcinoline acetonide, and an odorless form of the composition. | 2009-05-14 |
20090124587 | METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS - Methods for treating certain cancers in patients, such as mammals, using certain 17α-hydroxylase/C | 2009-05-14 |
20090124588 | Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions - The present invention is directed to compounds of formula (I): | 2009-05-14 |
20090124589 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. | 2009-05-14 |
20090124590 | PHARMACEUTICAL COMPOSITION - A pharmaceutical composition comprising: (A) an androgen; (B) a cyclic enhancer of the type used in the compositions and methods claimed by U.S. Pat. No. 5,023,252 to Hsieh; and (C) a thickening agent; including, for example, a composition in which the cyclic enhancer is a macrocyclic ester or a macrocyclic ketone; the use of the composition to treat a condition, for example, male hypogonadism, in a patient by applying the composition to the membrane of the patient; and a method for making the composition. | 2009-05-14 |
20090124591 | Synthesis and Use of Cationic Steroids for Anti-Inflammatory Drug Therapy - The invention relates to compositions and methods for a one-step synthetic technique for making cationic steroid pharmaceutical compositions for use in treating inflammation and other diseases and disorders. | 2009-05-14 |
20090124592 | PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING A PATHOLOGY ASSOCIATED WITH AN OBSESSIONAL BEHAVIOR OR WITH OBESITY - This invention relates to the use of a ligand of the 5-HT | 2009-05-14 |
20090124594 | INHALED AZTREONAM LYSINE FOR THE TREATMENT OF DEFICITS IN HEALTH-RELATED QUALITY-OF-LIFE IN LUNG DISEASES - Provided is a method of treating the health-related quality-of-life (HRQOL) symptoms of a lung disease, comprising the administration of an inhalable aerosole of aztreonam lysine. The method is suitable for the short term and sustainable long term treatment of HRQOL symptoms. | 2009-05-14 |
20090124595 | MAPK/ERK KINASE INHIBITORS - Compounds of the following formula are provided for use with MEK: | 2009-05-14 |
20090124596 | Chemical Compounds 637 - The present invention provides a compound of a formula (I): | 2009-05-14 |
20090124597 | SPIRO-CONTAINING COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS - Described herein are compounds that have a spiro structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of steroid hormone nuclear receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent diseases or conditions associated with the activity of steroid hormone nuclear receptors. | 2009-05-14 |
20090124598 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES - The use of substituted amides for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions, are described. Also a novel class of substituted amides, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments are described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable. | 2009-05-14 |
20090124599 | Fungicidal Mixtures - Fungicidal mixtures comprising, as active components
| 2009-05-14 |
20090124600 | N-Alkyl-Azacycloalkyl NMDA/NR2B Antagonists - Compounds represented by Formula (I): and/or pharmaceutically acceptable salts, individual enantiomers and stereoisomers thereof, are effective as NMDA/NR2B antagonists useful for treating conditions such as pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke. | 2009-05-14 |
20090124601 | Tartaric Acid Salts of a Dipeptidyl Peptidase-IV Inhibitor - Tartaric acid salts of (3R)-4-[(3R)-3-amino-4-(2,4,5-trifluorophenyl) butanoyl]hexahydro-3-(2,2,2-trifluoroethyl)-2H-1,4-diazepin-2-one are potent inhibitors of dipeptidyl peptidase-IV and are useful for the prevention and/or treatment of non-insulin dependent diabetes mellitus, also referred to as Type 2 diabetes. The invention also relates to crystalline anhydrate forms of the tartaric acid salts as well as a process for their preparation, pharmaceutical compositions containing these novel forms and methods of use for the treatment of Type 2 diabetes. | 2009-05-14 |
20090124602 | KINASE INHIBITORS - The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions. | 2009-05-14 |
20090124603 | Diazepan Orexin Receptor Antagonists - The present invention is directed to diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved. | 2009-05-14 |
20090124604 | 4-OXOQUINAZOLIN-3-YL BENZAMIDE DERIVATIVES FOR THE TREATMENT OF CYTOKINE DISEASES - The invention concerns a compound of the Formula (I) wherein m is 1-2 and each R | 2009-05-14 |
20090124605 | Pyrazolo-Quinazoline Derivatives, Process for Their Preparation and Their Use as Kinase Inhibitors - Pyrazolo-quinazoline derivatives of formula (Ia) or (Ib) as defined in the specification, and pharmaceutically acceptable salts thereof, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer. | 2009-05-14 |
20090124606 | Composition for Treatment of Psychosis - New pharmaceutical combination providing to decrease or eliminate the extrapyramidal side effects of antipsychotic active ingredients by combination of deramciclane with a classic antipsychotic agent (e.g. haloperidol, chloroprozamine or levoprozamin) or an atypical antipsychotic agent (e.g. risperidone, iloperidone or olanzapine). | 2009-05-14 |
20090124607 | Novel Bicyclic Sulfonamides for Use as Glucocorticoid Receptor Modulators in the Treatment of Inflammatory Diseases - Compounds of formula (I): or a pharmaceutically acceptable salt thereof; compositions comprising them, processes for preparing them and their use in medical therapy (for example modulating the glucocorticoid receptor in a warm blooded animal). | 2009-05-14 |
20090124608 | CB2 Receptor Modulators In Neurodegenerative Diseases And Applications Of The Same - Compositions for the treatment of neurodegenerative diseases are disclosed. Methods of treating and monitoring progression of a neurodegenerative disease are disclosed. According to the present invention, a selective CB2 receptor modulator may be administered to a mammal for the treatment of a neurodegenerative disease. | 2009-05-14 |
20090124609 | Fused heterocyclic derivatives and methods of use - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 2009-05-14 |
20090124610 | PHARMACEUTICAL COMPOUNDS - Compounds of the formula (I), and salts, solvates, tautomers and N-oxide thereof, wherein TG is selected from groups (1) and (2): wherein the asterisk (*) represents the point of attachment of the group E to the group X; R | 2009-05-14 |
20090124611 | Pyrazolopyridine-1,4-Diamines and Analogs Thereof - Pyrazolopyridine-1,4-diamines and analogs thereof, e.g., pyrazolo[3,4-c]pyridine-1,4-diamines, pyrazolo[3,4-c]quinoline-1,4-diamines, 6,7,8,9-tetrahydro pyrazolo[3,4-c]quinoline-1,4-diamines, and pyrazolo[3,4-c]naphthyridine-1,4-di-amines, pharmaceutical compositions containing the compounds, intermediates, methods of making these compounds, and methods of use of these compounds as immunomodulators, for inducing cytokine biosynthesis in animals and in the treatment of diseases including viral and neoplastic diseases are disclosed. | 2009-05-14 |
20090124612 | Fused heterocyclic derivatives and methods of use - Selected compounds are effective for prophylaxis and treatment of diseases, such as HGF mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes. | 2009-05-14 |
20090124613 | Substituted Heterocyclic Ethers and Their Use in CNS Disorders - The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders. | 2009-05-14 |
20090124614 | HYDROXY ALKYL SUBSTITUTED 1,3,8-TRIAZASPIRO[4.5]DECAN-4-ONE DERIVATIVES USEFUL FOR THE TREATMENT OF ORL-1 RECEPTOR MEDIATED DISORDERS - The present invention is directed to novel hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula | 2009-05-14 |
20090124615 | Benzimidazole Thiophene Compounds - The present invention provides benzimidazole thiophene compounds pharmaceutical compositions containing the same, processes for preparing the same and their use as pharmaceutical agents. | 2009-05-14 |
20090124616 | 7-NONSUBSTITUTED INDOLE MCL-1 INHIBITORS - Compounds which inhibit the activity of anti-apoptotic Mcl-1 protein, compositions containing the compounds, and methods of treating diseases involving overexpressed or unregulated Mcl-1 protein are disclosed. | 2009-05-14 |
20090124617 | QUINOLONE DERIVATIVE OR SALT THEREOF - A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor. | 2009-05-14 |
20090124618 | 2-MORPHOLINO-4-PYRIMIDONE COMPOUND - A compound represented by the formula (I), an optically active isomer thereof, or a pharmaceutical acceptable salt thereof: wherein X represents CH or N; represents a C | 2009-05-14 |
20090124619 | NOVEL COMPOUNDS - This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted morpholines and piperidines, according to Formula I | 2009-05-14 |
20090124620 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR - The present invention relates to an inhibitor of plasminogen activator inhibitor-1. The present invention further relates to a pharmaceutical composition that has an inhibitory action on PAI-1 activity and is useful in the prevention and treatment of various diseases whose onset is associated with PAI-1 activity. Furthermore, the present invention relates to a novel compound having PAI-1 inhibitory activity represented by the following general formula (I), and a salt thereof. | 2009-05-14 |
20090124621 | PYRAZOLE DERIVATIVES AS KINASE INHIBITORS - The present invention provides compounds having the general structure I, or a pharmaceutically acceptable salt thereof: | 2009-05-14 |
20090124622 | Medicament Containing a Thiazole Derivative as an Active Ingredient - A prophylactic and/or therapeutic agent for sinusitis, nasal obstruction•nasal mucosa congestion containing N-{2-[2-[(3-fluorophenyl)imino]-4-(4-morpholin-4-ylphenyl)-1,3-thiazol-3(2H)-yl]ethyl}-N′-methylurea represented by the formula (1) or its pharmaceutically acceptable salt as an active ingredient. | 2009-05-14 |
20090124623 | METHODS FOR PRESERVING AND/OR INCREASING RENAL FUNCTION USING XANTHINE OXIDOREDUCTASE INHIBITORS - The present invention relates to methods of preserving or increasing renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. The present invention also relates to methods of increasing renal function in a subject in need thereof by administering a therapeutically effective amount of at least one xanthine oxidoreductase inhibiting compound or salt thereof. | 2009-05-14 |
20090124624 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF - The invention concerns 1-amino-phthalazine derivatives of general formula (I): | 2009-05-14 |
20090124625 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS - The present invention relates to novel compounds of formula (I) wherein W, n, X and W′ are defined in the description; invention compounds are modulators of metabotropic glutamate receptors—subtype 5 (“mGluR5”) which are useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors. | 2009-05-14 |
20090124626 | Pharmaceutical agent comprising insulin resistance improving agent - To provide a method for treating diabetes which has an excellent hypoglycemic action and causes minimal adverse drug reactions, there is provided a medicine comprising a DPP-IV inhibitor and an insulin sensitizer in combination. | 2009-05-14 |
20090124627 | COMPOSITIONS FOR SLEEPING DISORDERS - Provided herein is a method for treating, preventing, or ameliorating a disorder such as insomnia or another sleeping disorder using a composition that contains an effective amount of one or more compounds. | 2009-05-14 |
20090124628 | 2-benzylaminodihydropteridinones, process for their manufacture and use thereof as medicaments - The present invention relates to new 2-benzylaminodihydropteridinones of general formula (I) | 2009-05-14 |
20090124629 | 3-(1,2,4-TRIAZOL-3YLALKYL) AZABRICLO (3.1.0) HEXANE DERIVATIVES AS MODULATORS OF DOPAMINE D3 RECEPTORS - The present invention relates to novel compounds of formula (I) or pharmaceutically acceptable salt thereof: | 2009-05-14 |
20090124630 | 3, 4-DIHYDRO-2-NAPHTHAMIDE DERIVATIVES AS SELECTIVE DOPAMINE D3 LIGANDS - The invention relates to 3,4-dihydro-2-naphthamide derivatives of formula (I), pharmaceutical compositions containing them and their therapeutic applications as partial agonists or antagonists of the dopamine D3 receptor for the treatment of neuropsychological disorders. | 2009-05-14 |
20090124631 | Combination Therapy - The invention relates to the treatment of mammalian diseases manifested by abnormal cell growth and/or abnormal cell proliferation. More particularly, the invention relates to the use of combination therapies to control abnormal cell growth and/or abnormal cell proliferation. In particular, the invention relates to the use of isotype-selective inhibitors of histone deacetylases 1, 2 and/or 3 (HDACs 1-3), as well as isotype-selective inhibitors of HDAC1 and/or HDAC2, to potentiate therapeutic activity of microtubule-stabilization agents. | 2009-05-14 |
20090124632 | Methods and kits related to the topical administration of quinolone antibiotics.degree. - The present invention is generally directed to the treatment of dermatological bacterial infections, burns and wounds. It is more specifically directed to the treatment of such infections, burns and wounds using one or more quinolone antibiotics. In one method of treatment aspect, an aqueous solution containing Ciprofloxacin-HCl is topically applied to the skin of a patient exhibiting a dermatological disorder. In another method of treatment aspect, an ointment containing Ciprofloxacin-HCl is topically applied to the skin of a patient exhibiting a dermatological disorder. | 2009-05-14 |
20090124633 | N-OXIDES OF HETEROCYCLIC SUBSTITUTED BISARYLUREAS FOR TREATING KINASE-MEDIATED DISEASES - The present invention relates to heterocyclic substituted N-Oxides of formula I, the use of the compounds of formula I as inhibitors of one or more kinases, the use of the compounds of formula I for the manufacture of a pharmaceutical composition and a method of treatment, comprising administering said pharmaceutical composition to a patient. | 2009-05-14 |
20090124634 | Novel dipodazine compounds and applications - The invention relates to a novel class of dipodazine derivatives, suitable for use as surface on-growth inhibiting agents. | 2009-05-14 |
20090124635 | CHEMICAL COMPOUNDS - The present invention provides compounds of formula (I) wherein R | 2009-05-14 |